advertisement
Abstract #6176 Published in IGR 2-2
Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure
Stewart WC; Sharpe ED; Harbin TS Jr; Pastor SA; Day DG; Holmes KT; Stewart JAAmerican Journal of Ophthalmology 2000; 129: 723-727
PURPOSE: To evaluate the efficacy and safety of brimonidine compared with dorzolamide given three times daily as monotherapy in patients with primary open-angle glaucoma or ocular hypertension. METHODS: In a double-masked, multicenter, crossover comparison in 40 patients, qualified patients were washed out from their previous medication and randomized to dorzolamide 2% or brimonidine 0.2% for the first six-week treatment period. Patients then were washed out for two weeks and started on the opposite medication for the second six-week period. RESULTS: Baseline intraocular pressure for all 40 subjects (76 eyes) was 24.1 ± 2.0 mmHg. This study found that the 8:00 AM trough intraocular pressure after six weeks of therapy for dorzolamide was 20. 7 ± 3.1 mmHg and for brimonidine 20.8 ± 3.2 mmHg (p = 0.99). The peak intraocular pressure (two hours after dosing) for dorzolamide was 18.6 ± 3.4 mmHg and for brimonidine 17.8 ± 2.7 mmHg (p = 0.10). Dorzolamide caused more stinging upon instillation (p < 0.01) and brimonidine more itching (p = 0.01). No statistical differences existed between groups for systemic adverse events. Six patients, all on brimonidine, were discontinued from a treatment period early. Of these, two were discontinued for inadequate pressure control, two with dizziness and fatigue, one with ocular pain, and one for lifestyle reasons (p = 0.07). CONCLUSIONS: This study found similar efficacy and safety between monotherapy treatment with dorzolamide or brimonidine when each was given three times daily to patients with ocular hypertension or primary open-angle glaucoma.
Dr. W.C. Stewart, Pharmaceutical Research Corporation, Charleston, SC 29412-2464, USA
Classification:
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
